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Abstract
Butyrate is a short chain fatty acid derived from the microbial fermentation of dietary fibers in the colon. In the last
decade, multiple beneficial effects of butyrate at intestinal and extraintestinal level have been demonstrated. The
mechanisms of action of butyrate are different and many of these involve an epigenetic regulation of gene
expression through the inhibition of histone deacetylase. There is a growing interest in butyrate because its impact
on epigenetic mechanisms will lead to more specific and efficacious therapeutic strategies for the prevention and
treatment of different diseases ranging from genetic/metabolic conditions to neurological degenerative disorders.
This review is focused on recent data regarding the epigenetic effects of butyrate with potential clinical
implications in human medicine.
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Introduction
The intestinal microbiota plays a critical role in the
establishment and maintenance of body health. Com-
mensal bacteria are involved in the fermentation of diet-
ary fibers in the colon leading to production of short
chain fatty acids (SCFAs), 2-carbon to 5-carbon weak
acids including acetate (C2), propionate (C3), butyrate
(C4) and valerate (C5). Among the SCFAs, butyrate has
received particular attention for its multiple beneficial
effects from the intestinal tract to the peripheral tissues
[1]. The most important butyrate producers appear to be
Faecalibacterium prausnitzii, which belongs to the Clos-
tridium leptum (or clostridial cluster IV) cluster, and
Eubacterium rectale/Roseburia spp., which belong to the
Clostridium coccoides (or clostridial cluster XIVa) cluster
of firmicute bacteria [2]. The mechanisms of action of
butyrate are multiple, but many of these are related to its
regulatory effects on gene expression. Butyrate is part of
a well known class of epigenetic substances known as his-
tone deacetylase inhibitors (HDACi). Epigenetics focuses
on the mechanisms that mold chromatin structures and
regulate gene expression with stability, thus defining cell
identity and function and adapting cells to environment,
without changing the nucleotide sequence. There are
three distinct, but closely interacting, epigenetic mechan-
isms (histone acetylation, DNA methylation, and non-
coding microRNAs) that are responsible for modifying
the expression of critical genes associated with physiolo-
gic and pathologic processes [3]. Histone tail acetylation
is believed to enhance the accessibility of a gene to the
transcription machinery, whereas deacetylated tails are
highly charged and believed to be tightly associated with
the DNA backbone, thus limiting accessibility of genes to
transcription factors [4]. Modulation of histone acetyla-
tion and deacetylation through environmental factors,
including dietary compounds, may prevent diseases and
maintain health. In a broader context, there is a growing
interest in dietary HDACi, in particular butyrate because
its impact on epigenetic mechanisms will lead to more
specific and efficacious therapeutic strategies in the pre-
vention and treatment of different diseases. This review
is focused on recent data regarding the epigenetic effects
of butyrate with potential clinical implications in human
medicine.
Cancer therapy and chemoprevention
Recently, in the area of cancer biology increasing atten-
tion has been given to the role of epigenetic alterations
in the etiology of cancer. A particularly active field of
research involves HDACi, not only for cancer therapy
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but also for cancer chemoprevention. In contrast to
genetic defects, epigenetic aberrations can be reversible:
a trait that represents a key aspect of their potential as
therapeutic targets. HDACi cause changes in the acety-
lation status of chromatin and other non-histone pro-
teins, resulting in changes in gene expression, induction
of apoptosis, cell cycle arrest, and inhibition of angio-
genesis and metastasis [5,6]. Several HDACi are involved
in various stages of development, including clinical trials
as monotherapies and in combination with other antic-
ancer drugs and radiation treatments [7,8]. However,
the molecular mechanisms underlying the response to
HDACi in cancer patients are not fully understood.
Butyrate and phenylbutyrate are on the market for non-
oncologic uses for years and have been shown to have
HDACi activity. These SCFAs have HDACi activity at
millimolar concentrations. The ability of butyrate to de-
repress epigenetically silenced genes in cancer cells,
such as cell cycle inhibitor p21 and the proapoptotic
protein Bcl-2 homologous antagonist/killer (BAK), and
to activate these genes in normal cells, has important
implications for cancer prevention and therapy [9].
HDACi can also induce autophagic cell death. HeLa
cells with apoptotic protease activating factor 1 (Apaf-1)
knockout or B cell lymphoma-extra large (Bcl-XL) over-
expression were induced to autophagic cell death with
autophagic vacuoles in the cytoplasm, when cultured
with butyrate [10,11]. Furthermore, HDACi have been
described to have antiangiogenic and antimetastatic
effects. Butyrate was found to repress angiogenesis in
vitro and in vivo, and reduce expression of proangiogen-
esis factors, including hypoxia inducible factors (HIF-1a)
and vascular endothelial growth factor (VEGF) [12-14].
Several studies have hypothesized that an increased
colonic concentration of butyrate can be an important
mediator in the observed protective effect of fermenta-
ble dietary fibers against colorectal cancer [15,16]. The
protective role of dietary fibers and their breakdown
product butyrate against colorectal cancer could be
determined by a modulation of canonical Wnt signaling,
a pathway constitutively activated in the majority of col-
orectal cancers [17]. Butyrate is recognized for its poten-
tial to act on secondary chemoprevention by slowing
growth and activating apoptosis in colon cancer cells,
but it can also act on primary chemoprevention [18].
The mechanism proposed is the transcriptional upregu-
lation of detoxifying enzymes, such as glutathione-S-
transferase (GST). The modulation of the GST gene
may protect cells from genotoxic carcinogens, such as
H2O2 and 4-hydroxynonenal (HNE) [19,16]. A new
compound named pivanex (pivaloyloxymethil butyrate)
has demonstrated an antineoplastic activity in the treat-
ment of non-small-cell lung cancer. Its effect is based
on a rapid hydrolysis and release of butyrate, permitting
efficient delivery to subcellular targets. Pivanex has been
shown to be active and safe in pretreated non-small-cell
lung cancer patients and these interesting results led
this drug to be administered in combination with doce-
taxel [20].
Anti-inflammatory effects
The principle mechanisms through which butyrate exerts
its anti-inflammatory effects are the suppression of
nuclear factor B (NFkB) activation, the inhibition of
interferon g production and the upregulation of peroxi-
some proliferator-activated receptor g (PPARg), which
may result from the inhibition of HDAC [21]. These
properties of butyrate led us to evaluate its possible ther-
apeutic use in inflammatory bowel disease (IBD). Inter-
vention studies in patients with ulcerative colitis (UC)
suggested that the luminal administration of butyrate or
stimulation of luminal butyrate production by the inges-
tion of dietary fibers results in an amelioration of the
inflammation and symptoms [22,23]. Hallert et al.
instructed 22 patients with quiescent UC to add 20 g of
dietary fibers to their daily diet. A total of 4 weeks of this
treatment resulted in a significant increase of fecal buty-
rate concentration and in a significant improvement of
abdominal symptoms [22]. Vernia et al. in a double-
blind, placebo-controlled multicenter trial, treated 51
patients with active distal UC with rectal enemas con-
taining either 5-aminosalicylic acid (5-ASA) or 5-ASA
plus sodium butyrate (80 mM, twice a day). The com-
bined treatment with topical 5-ASA plus sodium butyrate
resulted in a significant improvement of the disease activ-
ity score compared to that observed in patients treated
with 5-ASA alone [23].
Effects on obesity, insulin resistance and cardiovascular
diseases
The anti-inflammatory effect of butyrate, mediated by
inhibition of HDAC, may also be able to prevent the infil-
tration of immune cells from the bloodstream in the adi-
pose tissue [24]. In this regard, it could be interesting to
evaluate butyrate in the prevention/treatment of chronic
low grade inflammation, frequently seen in obesity and
associated with an increased risk of insulin resistance,
type 2 diabetes, and cardiovascular diseases. In a preclini-
cal study, Gao et al. showed that dietary supplementation
of butyrate can prevent and treat diet-induced obesity
and insulin resistance in mouse models. Butyrate acts
through a stimulation of peroxisome proliferator-acti-
vated receptor-g coactivator 1a (PGC-1a) activity, which
results from the inhibition of HDAC and the activation
of AMP-activated protein kinase (AMPK) [25]. In
hypercholesterolemia, recent evidence shows that the
global effect of butyrate is to downregulate the expres-
sion of nine key genes involved in intestinal cholesterol
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biosynthesis, thus possibly inhibiting this pathway [26].
These data suggest that butyrate may have potential
application in the prevention and treatment of the main
components of the so-called metabolic syndrome in
humans. Moreover, butyrate showed to have a more
direct protective role in cardiovascular diseases. Recently,
Mathew et al. demonstrated that butyrate exhibits ather-
oprotective/antiatherogenic potential by altering G1-spe-
cific cell cycle proteins through its chromatin remodeling
activity to arrest vascular smooth muscle cells prolifera-
tion, a critical cellular component of the blood vessel,
that play a major role in the development of athero-
sclerosis. The results of this study suggest a potential role
for butyrate both in cardiovascular disease prevention
and in therapeutic intervention of arterial restenosis and
in-stent restenosis as a pharmacological agent, respec-
tively [27].
Effects on the immune system
Another emerging area of research involves the epige-
netic regulation of the immune system exerted by buty-
rate. Epigenetic pathways act at many levels to regulate
immune functions: in immune system development, in
response to infection, in immune surveillance to tumors
and in autoimmunity [28]. In particular, butyrate seems
to exert broad anti-inflammatory activities by affecting
immune cell migration, adhesion, cytokine expression as
well as affecting cellular processes such as proliferation,
activation and apoptosis [24]. The effects of butyrate are
also exerted on the innate immune system. The antimi-
crobial protein cathelicidin plays an important role in the
defense mechanisms against bacterial infection. Several
studies show that sodium butyrate induces cathelicidin
gene expression in human colonic, gastric and hepatic
cells [29-31]. Kida et al. investigated the mechanisms
involved in sodium butyrate-induced cathelicidin gene
expression in a human lung epithelial cell line, EBC-1.
This study indicated that sodium butyrate could induce
both the cathelicidin mRNA and protein expression.
Furthermore, they demonstrated that activator protein 1
(AP-1) and histone acetylation of cathelicidin promoter
participate in the regulation of inducible cathelicidin
gene expression [32]. Thus, the use of HDACi to enhance
the expression of cathelicidins may become a novel
approach of strengthening innate immunity.
Effects on inherited disorders
Butyrate can also be considered an inducer of fetal hemo-
globin (HbF) synthesis, an interesting strategy for the
treatment of b-hemoglobinopathies, such as sickle cell dis-
ease and b-thalassemia. The induction of HbF synthesis
involves the epigenetic regulation of g-globin gene expres-
sion, which is mediated by HDAC inhibition. Clinical trials
in patients with sickle cell disease and b-thalassemia
confirmed the ability of butyrate to increase HbF produc-
tion [33,34].
Butyrate and its derivatives have been investigated as a
potential approach for the treatment of cystic fibrosis
[35]. Class II mutations of cystic fibrosis transmembrane
conductance regulator (CFTR) can be restored to the
protein trafficking pathway by manipulation of chaperone
protein/CFTR interactions with chemical chaperones or
drugs that affect gene regulation such as butyrate. Inves-
tigations have demonstrated in vitro activity in the form
of increased production of mature CFTR and chloride
transport at the cell surface. The mechanism is still not
fully understood but is likely to involve upregulation at
the transcriptional level and modulation of protein fold-
ing step. Butyrate is likely to show activity for other
inherited disorders with alternative enzymatic pathways
that could be upregulated, such as X-linked adrenoleuko-
dystrophy (X-ALD), a disorder of peroxisomes due to
mutations in ABCD1 gene and characterized by altered
metabolism and accumulation of very long chain fatty
acids. Histone deacetylase inhibitors reduce the oxidative
damage in X-ALD cells, moreover they could induce the
expression of the closest homolog of ABCD1, the redun-
dant gene ABCD2, which should be able to compensate
for the lack of functional ABCD1 in X-ALD patients [36].
Congenital chloride diarrhea (CLD) is another inherited
disorder in which butyrate therapy has been shown to be
beneficial [37,38]. CLD is a rare genetic disease caused by
mutations in the gene encoding the solute-linked carrier
family 26-member A3 (SLC26A3) protein, which acts as
a plasma membrane anion exchanger for Cl- and HCO3
-.
The mechanism underlying this therapeutic effect could
be related to stimulation of the Cl-/butyrate exchanger
activity, to reduction of mistrafficking or misfolding of
the SLC26A3 protein, or alternatively butyrate may
induce the expression of SLC26A3 gene, which contains
a 290-bp region between residues -398 and -688 that is
crucial for high-level transcriptional activation induced
by butyrate. This may explain the variable response of
patients affected by CLD to butyrate; in fact, depending
on the patient’s genotype, mutations in the above-men-
tioned regulatory regions of the SLC26A3 gene could
affect gene transcription rate.
Neuroprotective effects
A new field of application of butyrate is in ischemic
stroke: butyrate seems to have long-term beneficial
effects after ischemic injury. Cerebral ischemia enhances
neurogenesis in neurogenic and non-neurogenic regions
of the ischemic brain of adult animal models. A preclini-
cal study demonstrated that post-insult treatment with
sodium butyrate stimulated cell proliferation, migration
and differentiation through the upregulation of the brain-
derived neurotrophic factor (BDNF) in the ischemic brain
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of rats subjected to permanent cerebral ischemia [39].
Butyrate also exerts significant neuroprotective effects in
a transgenic mouse model of Huntington’s disease (HD),
and therefore represents a very promising therapeutic
approach for HD. There is evidence that mutant Hun-
tington protein interacts with transcription factors lead-
ing to reduced histone acetylation. Administration of the
HDACi phenylbutyrate after onset of symptoms in a
transgenic mouse model of HD significantly extends sur-
vival and attenuates neuronal atrophy [40]. Other inter-
esting effects of butyrate are those that were observed on
memory. Blocking HDAC activity with non-specific
HDACi, such as sodium butyrate, enhances synaptic plas-
ticity and memory, suggesting that HDACs may actually
serve to return chromatin to a repressive state and
silence transcription required for long-term memory for-
mation [41]. Moreover, HDAC inhibition can transform
a learning event that does not normally lead to long-term
memory for object recognition into a long-lasting form
of memory [42]. Together, these results suggest HDACs
may serve as critical memory suppressor genes and show
that HDACi, such as butyrate, may generate more persis-
tent forms of long-term memory, which has great thera-
peutic and translational value.
Effects on stem cells
Butyrate greatly enhances the efficiency of induced pluri-
potent stem cell derivation from human adult or fetal
fibroblasts by promoting epigenetic remodeling and the
expression of pluripotency-associated genes [43]. Thus,
butyrate as a cell permeable small molecule provides a
simple tool to further investigate molecular mechanisms
of cellular reprogramming. Moreover, butyrate stimula-
tion provides an efficient method for reprogramming var-
ious human adult somatic cells, including cells from
patients that are more refractory to reprogramming. Dif-
ferent evidence suggests that cancer stem-like cells exist
in several malignant tumors, such as leukemia, breast
cancer, and brain tumors, and that these stem cells
express surface markers similar to those expressed by
normal stem cells in each tissue [44-46]. In a recent
study, Kato et al. isolated side-population cells and non-
side-population cells derived from a rat endometrial cell
line expressing human [12Val] KRAS (RK12V cells) and
determined the side-population phenotype. RK12V-SP
cells showed self-renewal capacity, the potential to
develop into stromal cells, reduced expression levels of
differentiation markers, long-term proliferating capacity
in cultures, and enhanced tumorigenicity, indicating that
RK12V-SP cells have cancer stem-like cell features.
RK12V-SP cells also display higher resistance to conven-
tional chemotherapeutic drugs. In contrast, treatment
with sodium butyrate reduced self-renewal capacity and
completely suppressed colony formation of RK12V-SP
cells in a soft agar, demonstrating an inhibitory effect of
sodium butyrate on proliferation of endometrial cancer
stem-like cells [47].
Conclusions
The gastrointestinal tract contributes to body health in
many ways. Of particular interest in this context is the
emerging concept of ‘gut health’ and the mechanisms that
can explain it. ‘Gut health’ is a term increasingly used in
the medical literature. It covers multiple positive aspects
of the gastrointestinal tract, such as the absence of gastro-
intestinal illness, normal and stable intestinal microbiota,
and effective immune status, that are also able to deter-
mine a state of well-being [48]. There is now ample evi-
dence that two functional entities are crucial to achieve
and maintain ‘gut health’ [49,50]. These entities are the
intestinal microbiota and the intestinal barrier. Any
impairment of the intestinal microbiota, for example,
deriving from an unbalanced diet such as a carbohydrate-
rich diet, could affect gut functionality and consequently
‘gut health’ [51]. Thus, ‘gut health’ can offer a new
approach for preventive medicine if we learn more about
how to achieve and maintain it. Lifestyle characteristics,
such as a balanced diet, moderate but regular exercise and
avoidance of chronic stress, but also defined products
such as select prebiotics and probiotics, can support gut
health [48]. In this context, the important role of intestinal
microflora in the production of SCFAs from the earliest
stages of life has lead to the idea that probiotics represent
a novel therapeutic or preventive strategy for chronic dis-
eases, restoring SCFA levels by modulating the microbial
environment (Figure 1) [52]. More recently, Licciardi et al.
hypothesized that the epigenetic mechanisms elicited by
probiotics through the production of SCFAs, especially
butyrate, are the key to understand how they mediate
their numerous health promoting effects from the gut to
the peripheral tissues [53]. Butyrate has a pivotal role in
the context of ‘gut/body health’. Its production is depen-
dent on diet and intestinal microflora composition, but it
is also able to modulate intestinal microflora through reg-
ulation of lumen pH and to exert many beneficial extrain-
testinal effects through epigenetic mechanisms [52]. In a
broader context, butyrate may be useful in the prevention
and treatment of different chronic disorders, including
cancer, metabolic syndrome, cardiovascular diseases,
inherited disorders, immune-mediated chronic disorders,
and neurodegeneration. Moreover, butyrate might help
with developing improved strategies for regenerative medi-
cine by promoting epigenetic remodeling and the expres-
sion of pluripotency-associated genes. In conclusion,
numerous preclinical data have been obtained in the last
decade, and these findings provide the basis for future
clinical studies aiming to elucidate the potential preventive
and therapeutic role(s) of butyrate in human medicine.
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